Idexx Laboratories, Inc. (NASDAQ: IDXX) started the day on Wednesday, with a price decrease of -5.02% at $468.04, before settling in for the price of $492.76 at the close. Taking a more long-term approach, IDXX posted a 52-week range of $372.50-$583.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 10.69% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 18.76%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 10.78%. This publicly-traded company’s shares outstanding now amounts to $83.03 million, simultaneously with a float of $82.27 million. The organization now has a market capitalization sitting at $38.89 billion. At the time of writing, stock’s 50-day Moving Average stood at $527.41, while the 200-day Moving Average is $503.32.
Idexx Laboratories, Inc. (IDXX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Diagnostics & Research Industry. Idexx Laboratories, Inc.’s current insider ownership accounts for 0.99%, in contrast to 89.82% institutional ownership. According to the most recent insider trade that took place on Mar 06 ’24, this organization’s Executive Vice President sold 8,104 shares at the rate of 558.44, making the entire transaction reach 4,525,596 in total value, affecting insider ownership by 10,711. Preceding that transaction, on Mar 05 ’24, Company’s Director sold 1,404 for 562.98, making the whole transaction’s value amount to 790,427. This particular insider is now the holder of 1,216 in total.
Idexx Laboratories, Inc. (IDXX) Earnings and Revenue Records
Idexx Laboratories, Inc.’s EPS increase for this current 12-month fiscal period is 10.78% and is forecasted to reach 12.73 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 12.00% through the next 5 years, which can be compared against the 18.76% growth it accomplished over the previous five years trading on the market.
Idexx Laboratories, Inc. (NASDAQ: IDXX) Trading Performance Indicators
Let’s observe the current performance indicators for Idexx Laboratories, Inc. (IDXX). It’s Quick Ratio in the last reported quarter now stands at 1.11. The Stock has managed to achieve an average true range (ATR) of 13.17. Alongside those numbers, its PE Ratio stands at $46.51, and its Beta score is 1.27. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.62. Similarly, its price to free cash flow for trailing twelve months is now 50.32.
In the same vein, IDXX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 10.06, a figure that is expected to reach 2.97 in the next quarter, and analysts are predicting that it will be 12.73 at the market close of one year from today.
Technical Analysis of Idexx Laboratories, Inc. (IDXX)
If we take a close look at the recent performances of Idexx Laboratories, Inc. (NASDAQ: IDXX), its last 5-days Average volume was 0.62 million that shows progress from its year to date volume of 0.44 million. During the previous 9 days, stock’s Stochastic %D was recorded 53.48% While, its Average True Range was 14.10.
Raw Stochastic average of Idexx Laboratories, Inc. (IDXX) in the period of the previous 100 days is set at 4.98%, which indicates a major fall in contrast to 12.89% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 30.81% that was higher than 26.59% volatility it exhibited in the past 100-days period.
